Cancellation of 1 subsidiary and suspension of sales of 12 medicines

Bristol-Myers Squibb stated that the company's drug distribution and all businesses in China will not be affected by the above changes in any way
.
Bristol-Myers Squibb will continue to increase its investment in China
.
In addition, in the next five years, Bristol-Myers Squibb will accelerate the introduction of global innovative product lines and introduce nearly 30 innovative products or indications in China
.

Keep losing weight, another subsidiary cancelled a number of listed drugs

It is also worth noting that on March 1, the State Food and Drug Administration issued an announcement to cancel the registration certificates of 226 drugs
.
Wherein, American Shanghai Squibb Pharmaceutical Co.
active cancellation application 12 products: oral solution comprising ammonia caplets, acetaminophen chewable tablets, multi-dimensional sheet elements, captopril tablets, capsules and the like cephradine
.
The cancellation of the drug registration certificate means that this batch of drugs will be delisted for sale
.

In the shareholding structure, Bristol-Myers Squibb (China) Investment Co.
, Ltd.
only holds 60% of Sino-US Shanghai Squibb Pharmaceuticals Co.
, Ltd.
, Shanghai Pharmaceuticals Group Co.
, Ltd.
holds 30%, and Sinopharm Group Asset Management Co.
, Ltd.
holds 10 % Shares
.
The legal representative of Sino-US Shanghai Squibb Pharmaceutical Co.
, Ltd.
is Zuo Min
.
The company's business scope includes "manufacturing drugs, selling self-produced products in domestic and foreign markets, and independently operating, promoting, importing and exporting
.
It is engaged in drug research and development.
.
.
transferring self-research results and providing corresponding technical services
.
Provide marketing consulting services and trade information consulting services
.
"

Among the drugs cancelled this time by Sino-US Shanghai Squibb Pharmaceuticals Co.
, Ltd.
, captopril tablets were extremely fierce in the third batch of national procurement bids.
In the end, 8 domestic pharmaceutical companies won the bids, and the bids of these 8 winning companies were all between 1 and 3 points.
About money, it is already super low; currently there are more than 100 domestic companies producing and selling cefradine capsules.
In the second batch of national procurement bids, Huanan Pharmaceutical, Shandong Lukang, Xinhua Pharmaceutical, and Shandong Luoxin won the central procurement market
.

With the implementation of pharmaceutical policies such as the two-invoice system, mass purchase, and consistency evaluation, the domestic drug circulation and sales market have undergone tremendous changes
.
It is not difficult to see that Bristol-Myers Squibb has made some adjustments and changes in its sales of medicines in China, such as gradually abandoning the sale of some mature medicines
.

On February 4 this year, Bristol-Myers Squibb’s 2020 results showed that the total annual revenue reached US$42.
518 billion, an increase of 63% compared to 2019
.
Research and development investment also reached 11.
143 billion US dollars, an increase of 81.
2% year-on-year
.
After the acquisition of Xinji, the BMS listed product pipeline has Revlimid (lenalidomide), Eliquis (apixaban), Opdivo (nivolumab), Orencia (abatacept), Pomalyst (Pomalyst) Amine), these 5 products contribute a total of US$34.
5 billion in revenue
.
Among them, lenalidomide has become the new top brand of BMS, with annual sales reaching 12.
106 billion U.
S.
dollars; due to the impact of similar competing products, O drugs will experience a decline in performance for the first time in 2020, with annual sales of 6.
992 billion U.
S.
dollars.
A year-on-year decrease of 3.
0%
.

In addition to these five blockbuster drugs, newly listed drugs have also achieved good results
.
New drugs Reblozyl, Zeposia (Ozamod), Onureg (oral azacitidine) brought in a total of 138 million U.
S.
dollars in revenue last year.
BMS's pipeline of products under research also includes mavacamten and coagulation factor XIa inhibitors obtained from the acquisition of MyoKardia.
needle agent, First in Tyk2 class of inhibitors deucravacitinib the like
.

It is a common practice for large pharmaceutical companies to divest non-core assets to lose weight and focus more on core business
.
Whether it is cancelling its subsidiaries in China or delisting mature products, it seems that Bristol-Myers Squibb’s intentions of divestiture and slimming can be seen
.

We also further verified Bristol-Myers Squibb on the above-mentioned related issues, but the company has not yet received a reply
.
We will continue to pay attention
.